0.060
0.00 (0.00%)
| Previous Close | 0.060 |
| Open | 0.060 |
| Volume | 121,116 |
| Avg. Volume (3M) | 185,577 |
| Market Cap | 26,813,578 |
| Price / Sales | 3.35 |
| Price / Book | 2.65 |
| 52 Weeks Range | |
| Earnings Date | 30 Aug 2024 |
| Profit Margin | 1.97% |
| Operating Margin (TTM) | -0.16% |
| Quarterly Revenue Growth (YOY) | 131.10% |
| Total Debt/Equity (MRQ) | 33.81% |
| Current Ratio (MRQ) | 1.51 |
| Operating Cash Flow (TTM) | 1.39 M |
| Levered Free Cash Flow (TTM) | 4.23 M |
| Return on Assets (TTM) | -2.30% |
| Return on Equity (TTM) | 1.62% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Health Information Services (AU) | Mixed | Mixed |
| Health Information Services (Global) | Mixed | Bearish | |
| Stock | RESONANCE FPO [RHT] | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | -1.13 |
|
Resonance Health Ltd is a healthcare company specializing in the development and commercialization of technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment. Its product includes FerriScan, a non-invasive liver diagnostic technology used for the measurement of iron in the liver, Cardiac T2, and HepaFat-Scan. It also has several AI-assisted SaMDs including FerriSmart, HepaFat-AI, and LiverSmart. The company's business segments are; Services which derives key revenue, Research and development, Corporate, Clinical Research Organization (CRO), and TrialsWest. Geographically, it generates maximum revenue from the Asia Pacific and the rest from North America, and Europe, Middle East and Africa (EMEA) regions. |
|
| Sector | Healthcare |
| Industry | Health Information Services |
| Investment Style | Small Core |
| % Held by Insiders | 35.98% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |